NOXXON Pharma, Inc. announced that an independent Data Safety Monitoring Board has confirmed that the highest dose of NOX-A12 in combination with radiotherapy in the ongoing Phase I/II study in patients with brain cancer is safe and that the trial should continue as planned.
[NOXXON Pharma, Inc.]
7753456
{7753456:nan}
apa
50
1
162119
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
